Indium In-111 pentetreotide
Also known as: 111In-DTPA-octreotide, 111In-pentetreotide, Indium-111 pentetreotide, OctreoScan, pentetreotide, pentetreotide In-111, somatostatin receptor scintigraphy tracer
Source Indium In-111 pentetreotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Indium-111 pentetreotide (OctreoScan) is a radiolabeled somatostatin analog used for diagnostic SPECT imaging of somatostatin receptor-positive neuroendocrine tumors.
Mechanism of Action
Binds somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumor cells; the In-111 radiolabel emits gamma photons for SPECT imaging.
Routes of Administration
Goals & Uses
- Detection of occult primary NETsDiagnostic ImagingModerate
- Monitoring treatment responseOncology DiagnosticsModerate
- Staging and restaging of neuroendocrine tumorsOncology DiagnosticsHigh
- Neuroendocrine tumor imagingDiagnosisHigh
- Patient selection for somatostatin analogue therapyTheranosticsModerate
- Localization of neuroendocrine tumorsDiagnostic ImagingHigh
Contraindications
- Known hypersensitivity to octreotide or pentetreotideAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to pentetreotide or any componentAllergyHigh
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
Adverse Effects
- Radiation exposureRadiologicalUnknown
- Dizziness / headacheNeurologicalUncommon
- Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
- Hypersensitivity / anaphylaxisImmunologicalRare
- Injection site reactionsLocalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Hypoglycemia or hyperglycemiaMetabolicRare
Drug Interactions
- Total parenteral nutrition / lipid emulsionsLow
- Somatostatin analog therapy (e.g., octreotide)Low
- Octreotide (therapeutic doses)High
- LanreotideHigh
- Other radiopharmaceuticalsModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveAbsolute
- Pregnant womenReproductiveAbsolute
- Diabetic PatientsMetabolicRelative
Regulatory Status
- European UnionApprovedApproved: Diagnostic imaging of SSTR‑positive neuroendocrine tumors
- United StatesApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsMarketed as OctreoScan.
- United KingdomApprovedApproved: SPECT imaging of neuroendocrine tumors expressing somatostatin receptors
FDA‑approved (2003) for imaging of SSTR‑positive tumors; marketed as OctreoScan.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Indium In-111 pentetreotide?
Indium-111 pentetreotide (OctreoScan) is a radiolabeled somatostatin analog used for diagnostic SPECT imaging of somatostatin receptor-positive neuroendocrine tumors.
What is Indium In-111 pentetreotide used for?
Indium In-111 pentetreotide is educationally associated with: Detection of occult primary NETs, Monitoring treatment response, Staging and restaging of neuroendocrine tumors, Neuroendocrine tumor imaging, Patient selection for somatostatin analogue therapy, Localization of neuroendocrine tumors. Educational only — not medical advice.
How is Indium In-111 pentetreotide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Indium In-111 pentetreotide?
Reported adverse effects include: Radiation exposure, Dizziness / headache, Allergic reaction, Hypersensitivity / anaphylaxis, Injection site reactions, Hypotension, Flushing, Nausea, Hypoglycemia or hyperglycemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Indium In-111 pentetreotide?
Recorded contraindications: Known hypersensitivity to octreotide or pentetreotide, Pregnancy, Known hypersensitivity to pentetreotide or any component, Breastfeeding. Consult a qualified clinician before use.